论文部分内容阅读
据《Scrip》1998年3月20日报道,诺华公司的董事长Alex Krauer称,1997年诺华公司取得了很好的业绩,从而证明兼并是成功的。1997年该公司的销售增长了20％,营业利润增长了38％,为68亿瑞士法郎,合45亿美元,纯收入达到52亿瑞士法郎(合34.4亿美元),增长了43％。 在医疗保健领域,药品销售增长了22％,达到141亿瑞士法郎,合93.4亿美元;营业利润达到50亿瑞士法郎(合33.1亿美元),增长30.3％;研究开发费用为29.17亿瑞士法郎(合19.32亿美元),增长19.4％;营业利润销售增加了2.1％,达到26.7％。原因是销售量大幅度增长,生产效率获得提高,兼并使营销和分发的费用大大下降。为了在美国及其它地区打开新产品的销路,销售代表增加了1200位。产品审批成员从4位减到2位,以提高工作效率,
According to “Scrip” reported on March 20, 1998, Novartis chairman Alex Krauer said that in 1997, Novartis achieved a good performance, which proved that the merger was successful. In 1997, the company’s sales increased by 20%, operating profit increased by 38% to 6.8 billion Swiss francs, combined 4.5 billion US dollars, net income reached 5.2 billion Swiss francs (about 3.44 billion US dollars), an increase of 43%. In the healthcare sector, pharmaceutical sales increased by 22% to 14.1 billion Swiss francs, totaling US$ 9.34 billion; operating profit reached 5 billion Swiss francs (US$ 3.31 billion), an increase of 30.3%; research and development costs were 2.917 billion Swiss francs ( Combined $1.932 billion), an increase of 19.4%; operating profit sales increased by 2.1% to reach 26.7%. The reason is that the sales volume has increased substantially, production efficiency has increased, and the cost of marketing and distribution has been greatly reduced. In order to open sales of new products in the United States and other regions, sales representatives increased by 1,200. Product approval members are reduced from 4 to 2 to improve work efficiency.